Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B)

  • Michael B. Atkins
  • , Opeyemi A. Jegede
  • , Naomi B. Haas
  • , David F. McDermott
  • , Mehmet A. Bilen
  • , Mark Stein
  • , Jeffrey A. Sosman
  • , Robert Alter
  • , Elizabeth R. Plimack
  • , Moshe C. Ornstein
  • , Michael Hurwitz
  • , David J. Peace
  • , Sabina Signoretti
  • , Thomas Denize
  • , Alessia Cimadamore
  • , Catherine J. Wu
  • , David Braun
  • , David Einstein
  • , Paul J. Catalano
  • , Hans Hammers

Research output: Contribution to journal › Article › peer-review

23 Scopus citations

Fingerprint

Dive into the research topics of 'Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B)'. Together they form a unique fingerprint.

Medicine and Dentistry

Nursing and Health Professions